Physician profile
Alan R Plumer
NPI 1760405245
$6,566.08
in general payments reported to CMS, 2019-2025
31 companies · $1,704 in 2025
The $1,704 reported for 2025 was more than what 75% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,350 · 2020: $402 · 2021: $445 · 2022: $445 · 2023: $815 · 2024: $1,405 · 2025: $1,704.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,924.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,923.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,295.38 | 2019-2025 | |
| Janssen Biotech, INC. | $713.91 | 2019-2025 | Tremfya, Stelara, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $530.11 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $446.34 | 2019-2025 | Entyvio, Eohilia |
| Genzyme Corporation | $284.38 | 2022-2025 | |
| Pfizer INC. | $283.79 | 2019-2025 | |
| Madrigal Pharmaceuticals | $248.36 | 2024-2025 | Rezdiffra, Resmetirom |
| Qol Medical, LLC | $217.45 | 2019-2025 | Sucraid |
| Ardelyx, INC. | $165.19 | 2024-2025 | Ibsrela |
| Ferring Pharmaceuticals INC. | $164.63 | 2019-2025 | Rebyota |
| Phathom Pharmaceuticals, INC. | $136.40 | 2024-2025 | Voquezna |
| Romark Laboratories, Lc | $110.22 | 2019-2020 | |
| Ucb, INC. | $97.32 | 2019 | |
| Ironwood Pharmaceuticals, INC | $96.61 | 2019-2025 | Linzess |
| Cumberland Pharmaceuticals, INC. | $82.29 | 2023 | Kristalose |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $71.85 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $68.90 | 2022-2023 | |
| Gilead Sciences, INC. | $62.79 | 2020-2023 | |
| Allergan, INC. | $59.53 | 2019-2020 | |
| Exact Sciences Corporation | $55.59 | 2023-2024 | Cologuard Collection Kit |
| Novo Nordisk INC | $49.94 | 2025 | Wegovy |
| Celgene Corporation | $48.92 | 2023-2024 | Zeposia |
| Aimmune Therapeutics, INC. | $48.66 | 2024-2025 | Zenpep |
| Intercept Pharmaceuticals, INC. | $48.14 | 2019-2024 | |
| Lilly USA, LLC | $45.86 | 2024 | Omvoh |
| Janssen Scientific Affairs, LLC | $32.83 | 2021 | |
| Braintree Laboratories, INC. | $24.03 | 2019 | |
| Medtronic, INC. | $21.70 | 2021 | |
| Redhill Biopharma INC. | $21.03 | 2021 | |
| Alnylam Pharmaceuticals INC. | $20.91 | 2024 | Givlaari |
| Alfasigma USA, INC. | $13.02 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Plumer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.